Finally, serum FSTL3 partially mediated the association of increased NFS fibrosis risk and AMI in NAFLD and T2DM patients without adjusting for other factors, and explained 27.97% of the association (Fig. 4A). Here, FSTL3 is linked to metabolic dysfunction-associated steatotic liver disease.